Post-mortem studies conducted over the past 15 years suggest that apoptosis could play a role in the pathophysiology of bipolar disorder (BD) and, to a lesser degree, schizophrenia (SZ). To test this hypothesis, we have performed a post hoc analysis of an extant gene expression profiling database obtained from the hippocampus using a novel methodology with improved sensitivity. Consistent with the working hypothesis, BDs showed a marked upregulation of 19 out of 44 apoptosis genes; however, contrary to the hypothesis, the SZ group showed a downregulation of genes associated with apoptotic injury and death. These changes in the regulation of apoptosis genes were validated using quantitative RT-PCR. Additionally, antioxidant genes showed a marked downregulation in BDs, suggesting that accumulation of free radicals might occur in the setting of a previously reported decrease of the electron transport chain in this disorder. Overall, the changes seen in BDs and SZs do not appear to be related to exposure to either neuroleptics or mood stabilizers. We conclude that fundamental differences in the genetic regulation of apoptosis and antioxidant genes may help discriminate between the pathophysiology of BD and SZ and potentially point to new treatment strategies that are specific for each disorder.
Introduction
Post-mortem evidence gathered over the past 15 years has suggested that bipolar disorder (BD) and, to a lesser extent, schizophrenia (SZ) may involve apoptotic cell death. 1, 2 Several cell counting studies demonstrated a reduction of interneurons in the anterior cingulate cortex of schizophrenics, although this change has consistently shown a stronger covariation with affective disorder. [3] [4] [5] A more recent study using in situ end-labeling reported that there is a marked reduction of single-stranded DNA breaks in the anterior cingulate cortex of schizophrenics. 6 This finding suggested that in SZ there may be either a failure of apoptotic signaling pathways to proceed to DNA damage or alternatively there might be an activation of a DNA 'repair' enzyme. 6 We postulated that genes associated with the apoptotic cascade might be downregulated in SZ and upregulated in BD. To explore the question of whether there is an abnormal regulation of apoptosis in SZ and BD, gene expression profiling (GEP) has presented itself as a powerful screening tool, as it permits a broad evaluation at the level of cellular and molecular function. In an initial study in which this technology was employed and validated using quantitative RT-PCR (qRT-PCR), genes associated with the electron transport chain were found to be downregulated in BDs, but not in SZs. Contrary to our working hypothesis, the apoptosis pathways did not show appreciable changes in the hippocampus of either group.
It is important to emphasize, however, that the human hippocampus is composed of many different subregions, sublaminae and cellular subtypes that make it relatively difficult to detect subtle changes in the expression of genes in whole extracts of this region. This is particularly true when very stringent approaches to microarray analysis are employed. To improve the sensitivity of GEP in these studies, we have employed a low stringency approach to the analysis 8 of our microarray data. This methodology reduces the likelihood of Type II statistical errors, which can potentially be massive in microarray studies of complex brain regions, such as the hippocampus. Additionally, it is becoming broadly recognized that the hunt for disease genes requires methods for evaluating associations between multiple factors 9 and assessments of reliability. 10, 11 We have used GenMapp algorithms (www.genmapp.org) to evaluate changes in expression at the level of functional clusters and biopathways, rather than at the level of isolated genes. Using these strategies, we report here for the first time changes in the expression of genes associated with the apoptotic cascade in the hippocampus of BD and SZ subjects.
Methods
Briefly, the cohort of normal controls, schizophrenics and bipolars included in this study were matched for age and post-mortem interval and have been previously described in detail. 12 As shown in Table 1 , the normal control, schizophrenic and bipolar subjects were reasonably well matched for age, post-mortem interval, gender and hemisphere. All of the SZ subjects were treated with neuroleptic agents and all of the BD subjects were treated with lithium carbonate and/or other mood-stabilizing agents, including valproic acid, carbamazepine and clonazepam, during the year prior to death.
Preparation of RNA extracts
Total RNA extracts were obtained using the Totally RNA Kit from Ambion Inc. (Austin, TX, USA). Whole frozen hippocampi from each human case were homogenized (PowerGen 125, Fisher Scientific) in denaturation/lysis solution containing guanidinium thiocyanate and cationic detergents. The RNA was then recovered from each lysate in a two-step organic extraction. First, the lysate was mixed with an equal volume of phenol:chloroform:isoamyl alcohol, vortexed, chilled and centrifuged at 12 000 g. The resulting aqueous layer was transferred to a new tube, 1 10 th the volume of sodium acetate was added and the solution mixed vigorously. An equal volume of acidphenol:chloroform was then added and the solution was vortexed, chilled and centrifuged at 12 000 g. The resulting second aqueous phase was then drawn off and an equal volume of isopropanol was added. This preparation was stored at À201C for 1 h followed by centrifugation at 12 000 g for 20 min at 41C. The supernatant was aspirated off and the RNA pellets were resuspended in RNase-free dH 2 O/0.1 mM EDTA. To ensure the highest quality total RNA preparation, the extracts were processed further with a clean-up step involving passage over a Qiagen RNeasy minicolumn (Qiagen, Valencia, CA, USA), followed by series of ethanol/proprietary buffer washes. Enriched RNA was then eluted from the columns in RNase-free dH 2 O and stored at À701C. The quality of the RNA was assessed using an Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA, USA) to obtain 28S/18S ribosomal RNA ratios for each extract. Total RNA yield was determined from optical density readings at 260 nm with a SpectraMax Plus spectrophotometer (Molecular Devices, Sunnyvale, CA, USA).
Gene expression profiling Biotinylated target RNA was prepared from the total RNA extracts of each case according to recommended Affymetrix Protocols (flowchart at http://www.affy metrix.com/support/technical/datasheets/t7_datasheet. pdf). Total RNA (8 mg) was used for cDNA synthesis with a SuperScript II double-stranded cDNA synthesis kit (Invitrogen, Carlsbad, CA, USA). The SuperScript II kit employs a standard two-step reverse transcription reaction to generate cDNA complimentary to target mRNA. In vitro transcription of biotinylated RNA (bRNA) was performed with an Enzo-IVT kit (Affymetrix, Santa Clara, CA, USA), which utilizes T7 RNA polymerase to produce a linear amplification of target cDNA generated during the previous reverse transcription step. Target bRNA from each case was then fragmented and individually hybridized to the U-95A human genome array (Affymetrix) overnight in a 'rotisserie oven' at 451C. The microarrays were then stained on the Affymetrics fluidics station with two rounds of streptavidinphycoerythrin (Molecular Probes, Eugene, OR, USA) and one round of biotinylated anti-streptavidin antibody (Vector Labs, Burlingame, CA, USA). The microarrays were then scanned twice and visually inspected for evidence of artifacts, including 'edge' effects, bright spots or blemishes, that might have led to aberrant readings for genes located on those portions of the chips. The MicroArray Suite 5.0 Software (Affymetrix) was used to control the scanner, average the two images, define the probe cells and compute an intensity value for each cell. The data for each probe set (i.e. consisting of perfect match (PM) and mismatch (MM) probe cells for a given gene) were evaluated. Based on match-MM values for each probe pair, a discrimination score, R (R ¼ PMÀMM/ PM þ MM), was determined for each probe pair and 'present' and 'absent' calls were assigned to each probe set based on previously established detection P-values, alpha 1 (e.g. P ¼ 0.04) and alpha 2 (e.g. P ¼ 0.06), respectively.
Data analyses
General considerations. To analyze the microarray data, the Affymetrix Data Mining Tool Version 3.0 (DMT 3.0) was used to evaluate the quality of the chip data by assessing the expression indices, such as the 3 0 /5 0 ratios for glycerol-3-phosphate dehydrogenase (G3PDH) and b-actin, as well as the % Present Calls for each probe array. In addition, the DNA Chip Analyzer (dChip) software package 12 provided a statistical method for reducing errors due to nonspecific crosshybridizing probes and image contamination, 12 and generally yielded more robust findings when the PM model was used (see below).
Biopathway/cluster analyses. In order to identify biologically relevant clusters of inter-related genes, GenMapp algorithms (www.genmapp.org) were used to relate the dChip findings to several different biochemical pathways and/or biologically related clusters of genes. The first stage of the analysis involved selecting genes according to high and low stringency criteria for inclusion in the GenMapp biopathways analysis. The high stringency criterion was set at P ¼ 0.05 and this was progressively increased to 0.1, 0.15, 0.2 and 0.25, respectively. When P ¼ 0.1, the number of genes included in the GenMapp pathway analysis showed a discernible increase, which occurred almost exclusively in those pathways previously showing substantial activations when the P was set at 0.05. When the inclusionary criterion was increased in a stepwise manner to P ¼ 0.25, further increases in the number of genes entered into the GenMapp pathways were observed. However, in contrast to the situation that was observed with P ¼ 0.05 or 0.1, some of the GenMapp pathways that previously had not shown any activation began to show a random scatter of a small number of genes. This latter observation suggested that further increases of the inclusionary P-value would likely increase the background and compromise the signal-to-noise ratio of the post hoc analysis.
In order to use a more inclusionary strategy for the assessment of genes associated with multiple GenMapp biopathways/clusters, the statistical criterion for inclusion of a gene in post hoc analyses was broadened. An ad hoc metric was developed based on a combination of probability theory and two separate corrections for multiple comparisons. 8 A requirement for such an analysis is that changes in the hybridization of any particular gene to its probe sets must occur independently of probe sets for other genes. If the probe sets for all of the genes in one particular biopathway were all clustered within a discrete sector of a microarray, then the hybridization of the respective mRNAs to their appropriate probe sets could not be assumed to be independent of one another and probability theory could not be used for the analysis. The Affymetrix U-95A human genome microarrays employed in this study were tiled with dispersed probe sets, such that all 16-20 probe pairs representing a particular gene sequence were not positioned together. We considered whether the probe sets for several different genes associated with one particular biopathway might be similarly clustered together in one region of the chip and, if so, whether an artifact induced during processing could cause several clustered genes to show changes in expression that are dependent on the chip position. This hypothetical situation would be unlikely to occur; however, since the PM/MM ratio generated by the Affymetrix system must show a detectable signal (PM) over background (MM) in order for significant changes in expression to be detected. If a chip artifact were to influence the hybridization of RNA to the probes or perhaps the fluorescent emissions emanating from the probes, it would be difficult to observe significant changes in expression because the PM/ MM ratio would tend to not show a detectable signal over background for the genes in the cluster. In practice, when small disruptions in the expression profiles on a single region of the chip were observed, this portion of the chip was demarcated and excluded from the analysis. In our experience, when such chip defects do occur, they have not shown any apparent clustering of genes according to biopathways or function. Finally, visual inspection of microarrays for the location of single genes represented within a particular GenMapp pathway has demonstrated a broad degree of scatter, even when only the genes showing changes in expression are individually inspected. Based on these various considerations, we have concluded that the arrangement of the probe sets for the genes on the Affymetrix U-95A human genome microarrays is sufficiently independent of one another to justify the post hoc analysis based on probability theory.
In using this post hoc approach, a composite probability, P c , for each of the respective GenMapp pathways/clusters was computed by multiplying the individual P-values for each gene meeting inclusionary criteria (i.e. P 1 , P 2 yP i ). This number was divided by the ratio of the number of genes meeting high or low stringency criteria (n i ) and the number of genes potentially showing significant changes (n t ) in each pathway. The total number of GenMapp pathways examined (N p ) was also used to correct for multiple comparisons. The following equation expresses these relationships,
This equation provided two separate corrections for multiple comparisons by multiplying by both N p and n t . The a-level of significance for each GenMapp biopathway or cluster was established by examining the distribution of genes that met criteria for inclusion in the analysis and the final P c ¼ value obtained with the equation described above. Most GenMapp Figure 1 A set of diagrams showing the apoptosis pathways schizophrenics versus normal controls (upper) and bipolar disorder versus normal controls (lower). The genes show either an upregulation (red) or downregulation (blue), and the intensity of the color varies according to whether the inclusion criterion for a particular gene was P ¼ 0.05 ('high stringency') or P ¼ 0.25 ('low stringency'). The P-values are shown to the right for each gene. Using low stringency criteria, the apoptosis pathways for the bipolar subjects show 24 out of 44 genes with changes in expression. Of these, 19 are upregulated and only five are downregulated. For the schizophrenics, eight genes were upregulated and five were downregulated. In both cases, pivotal genes at the beginning of the apoptosis cascade show changes in regulation. Overall, the bipolars show an increase of proapoptotic changes not seen in the schizophrenics. pathways showed one or no genes meeting the stringency criteria and the P-values tended to be greater than 5 Â 10 -6 . A minority, however, showed two or more genes meeting the stringency criteria for inclusion and the resulting P c tended to be less than 5 Â 10
À6
. By visually comparing the pathways according to the number of genes showing changes in regulation and the resulting post hoc P c , it was apparent that those with a post hoc P c ¼ 5 Â 10 À6 appeared to show a significant amount of change and this number was chosen as the a-level for these post hoc analyses.
Fluorescence resonance energy transfer (FRET)-based qRT-PCR
In order to quantitate the amount of RNA associated with various target genes, a FRET approach to RT-PCR was employed. Total RNA used for qRT-PCR was obtained from RNA used in the microarray analysis (see above) for the normal control, schizophrenic and bipolar cases included in this study. First-strand cDNA was synthesized from 1 mg of total RNA using Superscript II reverse transcriptase and oligo-dT primers (Invitrogen). The 20 ml reaction volume was diluted five-fold for use in the PCR. Based on the expression profiles obtained in the microarray analysis, six genes were selected for qRT-PCR: Fas ligand (U11821), granzyme B (004131), Bcl-2 (M14745), APAF-1 (AF013263), c-myc (V00568), PARP-1 (poly(-adenosine diphosphate-ribosyl) polymerase) (32721) and GAPDH (M33197). As shown in Table 2 , primer pairs and dual-labeled hybridization probes were designed using web-based applications Primer3 (www.genome.wi.mit.edu) and the Oligo Toolkit (Integrated DNA Technologies). The sequence information for each of the primer pairs (i.e. forward and reverse) and the dual-labeled hybridization probes is shown in Table 2 . The PCR amplifications were performed on a Smartcycler (Cepheid, Sunnyvale, CA, USA) using Platinum Quantitative PCR Supermix-UDG (Invitrogen) with 300 nM primers and 150 nM fluorogenic probe. For the signal detection, Table 2 Sequence of primers and hybridization probes The sequences shown represent primer pairs and dual-labeled hybridization probes that were designed using web-based applications (www.genome.wi.mit.edu) and the Oligo Toolkit from Integrated DNA Technologies. The numbers in parentheses are the GenBank accession numbers for each gene. The number of base pairs associated with each primer is shown in the right column. The probes indicated in green serve as 'reporters' and the probes indicated in red serve as the 'quenchers.' For the target genes, either tetrachlorofluorescein (TET) or 6-carboxyfluorescein (6-FAM) was used as the reporter and 6-carboxytetramethylrhodamine (6-TAMRA) as the 'quencher.' For the 'housekeeping' gene GAPDH, Texas Red was used as the 'recorder' and Black Hole Quencher (BHQ-2) were used because they have spectral properties that are different from those for TET and 6-TAMRA, and this made it possible to run a duplex assay in which both a target and reference gene were analyzed in the same tube.
the Smartcycler was programmed to an initial step of 2 min at 501C and 2 min at 951C, followed by 45 thermal cycles of 15 s at 951C and 1 min at 601C. The threshold cycle C t , which correlates inversely with the target mRNA levels, was measured as the cycle number at which the reporter fluorescent emission increased significantly above a preset threshold level.
Relative standard curve methods were used to determine the transcript levels for all genes. Standard curves for all gene targets and constitutively expressed 'house-keeping gene', GAPDH, were constructed using serial dilutions of cDNA amplicons amplified from control templates. Differences in the total amount of RNA present in each target sample were normalized with respect to the reference gene using a relative expression software tool (REST) for group-wise comparison of the resulting expression ratios. 13 
Results
As shown in Table 1 , the quality control parameters, including the 3 0 /5 0 ratios for G3PDH and b-actin, % Present Calls and the 28S/18S ratios, were all equivalent for the three groups. As shown in Figure  1 , there were striking differences in the distribution of apoptosis genes in SZs versus BDs. There are some genes that showed changes in the same direction in both groups. For example, an upregulation of the proapoptotic factors RIP (receptor interfering kinase), caspase-2 and the antiapoptotic factors, MDM-2 and Bcl-x, were observed. In contrast, the proapoptotic factor BAX showed decreased expression in both the SZ and BD groups. The remainder of the apoptosis genes showed fundamental differences in regulation in the two disorders.
For the BDs, 24 out of a total of 44 genes in the apoptosis pathways satisfied the low stringency criterion for inclusion in the analysis (post hoc composite P c ¼ 2.9 Â 10 À27 ). As depicted in Figure 1 , there were several upregulated proapoptotic genes, including FAS ligand, FAS receptor 14, 15 perforin, 16 TNFa, 14, 17 c-Jun, 18 c-myc, 19 BAK, 20 APAF-1 and caspase-2 21 and -8. 14, 22 Other genes that are thought to inhibit apoptosis, such as TRAF1, IKK, IAP3, NF-kB 23 and Bcl-2, 24 also showed increased expression in the BD group, but these changes would tend to counteract the influence of the 10 upregulated proapoptotic genes, particularly when other key proapoptotic factors, such as JNKK, JNK, 25 were found to be downregulated. The DNA repair enzyme, PARP, 26 also showed a decrease in regulation.
When the BDs were broken down according to neuroleptic exposure, mRNA expression for the proapoptotic factors, FAS ligand, RIP, BID, TRAF1, FADD, MDM-2, caspase-2, p53 and c-myc, as well as the antiapoptotic factors, NIK, IKK and IAP3, were all increased in the drug-naïve BDs, while the proapoptotic factors JNKK and JNK, as well as the antiapoptotic factors, IAP2, NF-kB-p105 and PARP all showed decreased expression. The neuroleptic-free BD subjects also showed a decreased expression of PARP. For the neuroleptic-treated BDs, proapoptotic factors, such as perforin, TNFa, caspase-6, c-Jun, BAX, APAF-1 and caspase-2, all showed increased expression. Conversely, antiapoptotic factors, such as IKK, NF-kB-p105, NF-kB-p65, MCL-1, Bcl-2 and Bcl-x, were all upregulated in the BDs receiving neuroleptic. As shown in Table 3 , there was an overall increase of antiapoptotic changes in gene expression in the BDs, suggesting that neuroleptics may suppress apoptotic cell death in this disorder. The potential effect of mood stabilizers on changes in apoptosis gene expression was also considered; however, all of the BD subjects were actively treated with these agents at the time of death.
Numerous previous experiments suggest increases in oxidative stress promote an environment in which the accumulation of free radicals potentiates apoptosis. 27 To assess whether this potential mechanism may have contributed to cellular dysfunction, we identified a panel of 21 genes involved in the primary or secondary detoxification of reactive oxygen species (ROS) and are shown in Table 4 . Genes showing Data represent the number of genes showing changes in expression in relation to neuroleptic drug exposure. 'Proapoptotic' refers to genes associated with facilitation of the apoptosis cascade and cell death (e.g. BAX and APAF-1) that showed an increase of expression, or genes associated with an inhibition of apoptosis (e.g. Bcl-2 and MDM-2) that showed a decrease of expression. 'Antiapoptotic' refers to an increased expression of genes that inhibit apoptosis and a decreased expression of genes that facilitate apoptosis changes in expression in BDs included glutathione peroxidase 4, glyoxylase, esterase D-formylglutathione hydrolase, glutathione synthetase, glutathione S-transferase (the three, A2, M5 and omega, isoforms), catalase and superoxide dismutase (SOD). Neuronal nitric oxide synthase (NOS1) was upregulated.
In the SZ group, significant changes in the expression of genes associated with apoptosis were also observed (post hoc P c ¼ 4.3 Â 10 -9
), but there were differences with respect to the specific genes affected and the direction of the changes (refer to Figure 3) . Four proapoptotic genes (RIP, BID, JNK and caspase-2), and two prosurvival genes (Bcl-x and Bcl-2), showed an overall increase of expression. Other proapoptotic genes, such as granzyme B, 16, 28 caspase-8, 22, 29 MEKK1 19, 30 and c-myc, 19 showed decreased expression in the SZ group. These latter changes would tend to suppress the apoptotic potential of hippocampal cells, as these four factors are believed to play a critical role in facilitating the progression of apoptosis. When the SZ group was broken down according to 'low'-(CPZ-equivalent dose o500 mg/day; average ¼ 1897173 mg/day) and 'high'-(CPZ-equivalent dose 4500 mg/day; average ¼ 8167290 mg/day) dose neuroleptic exposure (Table 2) , the proapoptotic factors, Fas ligand, perforin, TRAIL, caspase-8, MEKK1, p53, c-myc, BAX and BAK, showed decreased expression in SZs receiving low-dose neuroleptic. Some prosurvival genes, such as TRAF1 and MDM-2, showed decreased expression, whereas others, such as Bcl-2, showed increased expression. In the 'high'-dose sub-group, the pattern observed was quite different. Several proapoptotic genes, including perforin, TRAIL, RIP, TNFa, caspase-2 and BAK, were upregulated, whereas antiapoptotic genes, such as IAP3, MCL-1 and PARP, were downregulated. Unlike the subjects with BD, the subjects with SZ showed no difference in the number of genes showing proapoptotic changes in expression. On the other hand, the number of genes showing antiapoptotic changes in expression was markedly reduced, suggesting that neuroleptics might have some ability to increase apoptotic potential in hippocampal cells of SZs. The DNA repair enzyme, PARP, showed a decrease of expression in the SZs treated with high-dose neuroleptic and this change could potentially increase the amount of DNA fragmentation present in these subjects. 6 This observation further supports the view that the decrease of DNA damage in SZ is probably not due to a neuroleptic effect. 6 As shown in Figure 2 , the microarray data for several apoptotic genes, including FAS ligand, gran- Data shown represent the gene expression profiling data for antioxidant genes in the hippocampus of bipolars and schizophrenics when compared to normal controls. The majority of genes show a downregulation in bipolars and several showed significant differences using conventional high stringency P-values.
zyme B, c-myc, PARP, BAK, Bcl-2 and APAF-1, were validated using qRT-PCR. In each case, the direction of change in expression for the CON, SZ and BD groups were consistent with that seen using the microarray approach, except that the magnitude of these differences were generally much greater. For example, in the case of c-myc, the fold changes were À5.2 and þ 5.4, respectively, in the SZs and BDs.
Although there was no change in PARP expression in the SZs when neuroleptic effects were not considered, the BDs showed an À8.2-fold decrease when compared to either the SZ or CON groups. Overall, the magnitude of the differences between the groups that were detected with qRT-PCR were much larger than those obtained with the microarrays and provided an important validation of the microarray results.
Conclusions
This study reports the results of a novel post hoc analysis of an extant microarray database, together with GenMapp biopathways and clusters, to obtain a more inclusive understanding of how complex aspects of transduction, signaling and metabolism may be altered in SZ and BD. Indeed, with this new methodology, it has been possible to detect marked changes in the regulation of genes associated with the apoptosis cascade, and would not have been detected, given the relative insensitivity of the standard approaches that employ an alpha level of P ¼ 0.05. 31 The more sensitive analysis described above has revealed robust changes in the expression of apoptosis genes in hippocampal cells in both SZ and BD subjects. Although there is some overlap in the genes showing differences in expression when compared to normal controls, the preponderance of such changes has been found to be remarkably different in SZs when compared to BDs. The hypothesis that apoptosis may play a role in the pathophysiology of SZ and BD can be traced to earlier microscopic studies in the anterior cingulate cortex 4, 32 and hippocampus, 33 which suggested that a loss of interneurons occurs in both disorders. These changes were found to be far more striking in BDs (30-35% reduction) when Standard curves for log concentration versus threshold cycle, like that shown for G3PDH, were established for each of the genes evaluated with qRT-PCR. In addition, mRNA for glyceraldehyde-3-phosphate dehydrogenase (G3PDH), a 'housekeeping' gene, was similar for the three groups (upper right hand) and this gene was used to normalize the data for the target genes (lower tier). As predicted from the microarray data, mRNA for c-myc was markedly decreased in schizophrenics, but increased in bipolars. In contrast, PARP was strikingly reduced in the bipolars, while schizophrenics showed no differences. Figure 3 Schematic diagrams depicting genes associated with the apoptosis cascade that show changes in expression in schizophrenia (upper) and bipolar disorder (lower). In schizophrenia, as postulated in an earlier study, 6 an overall downregulation of the apoptosis cascade, including granzyme B and caspase-8, in the cell periphery and the mitochondrialassociated antiapoptotic factors, BAX and c-myc, was observed. In bipolars, proapoptotic factors, including two death ligands, FAS and TNFa, as well as the FAS receptor, perforin, c-myc and BAK, were upregulated. NF-kB-p65 and -p105 were also upregulated, but the latter may play a role in stimulating the activity of the DNA repair enzyme, PARP-1, that was found to be downregulated. Antioxidant genes, such as SOD, catalase and GSH peroxidase, were significantly downregulated in BDs, suggesting that reactive oxygen, such as O 2 À , could be generated by the decreased mitochondrial electron transport activity reported previously, 12 might also contribute to DNA damage in BDs. Preliminary evidence is also suggesting that there is increased expression of L-type voltage-gated calcium channel activity (LVGCC) in BDs and this would exacerbate this situation. In SZs, antioxidant genes showed little change in regulation and LVGCC activity is probably also downregulated. Overall, the changes in bipolars would promote apoptotic injury or death, while those in schizophrenics would promote cell survival. compared to SZs (12-15% reduction), and it was postulated that there may be a more marked activation of apoptosis in affective disorder than in SZ. A subsequent study demonstrated that there was a paradoxical reduction in the amount of DNA damage present in the anterior cingulate cortex of schizophrenic subjects. 6 Indeed, the findings reported here are consistent with this latter observation, as there was a downregulation of several proapoptotic genes, such as granzyme B, caspase-8, c-myc and BAX. Based on the results reported here, it seems more likely that GABA cell pathology in SZ 34 may by related to a disturbance of intracellular signaling pathways, rather than to overt cell loss, as it appears to be the case in BD. 35 A noteworthy aspect of these findings is the observation that neuroleptic exposure was associated with a decrease of apoptotic potential in BDs, but an increase in SZs. Both typical 36 and atypical 37 antipsychotic drugs have been found to promote cell survival, although the atypical agents may be more effective in this regard. 38 Indeed, several atypical antipsychotic drugs appear to protect against DNA damage. 38 To date, only one neuroleptic, the typical agent perphenazine, has been associated with increased DNA fragmentation, 39 although one study has reported that clozapine may act as a hapten and increase inflammatory potential. 40 Contrary to the latter report, clozapine has also been found to activate Akt, 41 a prosurvival factor that, in turn, inhibits glycogen synthase kinase-3b (GSK-3b), a protein that drives intracellular signaling toward cell death via the Wnt pathway. Lithium carbonate, a standard moodstabilizing agent, is also believed to inhibit GSK-3b. 42 Both lithium and valproate have also been found to be associated with increased expression of Bcl-2 43, 44 and ultimately influence both signal transduction 42, 45, 46 and intracellular signaling cascades that are fundamental to cell survival. Accordingly, the upregulation of antiapoptotic genes in bipolar subjects is not explainable by exposure of the subjects to neuroleptic drugs and/or mood-stabilizing agents.
Overall, the data reported here are consistent with the working hypothesis that apoptosis may contribute to cell dysfunction in BD. 1 As depicted in Figure 3 , additional clusters of genes that play a central role in the clearance of free radicals generated by mitochondrial oxidation reactions, such as glutathione synthase, catalase and SOD, 27 also showed substantial decreases in expression in bipolars, but not schizophrenics. An upregulation of NOS1 could potentially contribute to apoptosis through increased excitotoxicity and or the generation of peroxynitrite radicals, which would increase due to diminished clearance by SOD, as suggested by the microarray data. This suggests that the accumulation of ROS associated with the oxidative stress would tend to potentiate damage to DNA, proteins and lipids. 47 In SZ, however, a downregulation of the apoptotic cascade may represent either an adaptive compensation to oxidative stress or a nonadaptive dysregulation of this pathway. 6 The absence of regulatory changes in the antioxidant pathways is consistent with this pattern. Additionally, we also have preliminary evidence suggesting that an L-type voltage-gated calcium channel is upregulated in bipolars and downregulated in schizophrenics. These latter changes would tend to increase and decrease, respectively, the apoptotic response of hippocampal cells in BDs versus SZs (refer to Figure 3) . 48, 49 It is important to emphasize that the interpretation of simultaneous changes in the expression of many genes that comprise complex signaling and metabolic pathway, such as apoptosis, is probably not straightforward, as it is likely that such changes may not be additive in nature. For example, it is theoretically possible that the activity of a single antiapoptotic gene could exert a stronger inhibitory effect than the summed influence of multiple proapoptotic factors. Given this caveat, however, the detection of differences in the regulation of apoptosis-related genes in BD and SZ may potentially lead to the development of specific and rational therapies directed at unique aspects of neuronal cell dysfunction in each disorder.
